Mansi Mathur, MPH, Ana Yankovsky, MSc, Matthew Lien, MS, PharmD, Usha Kreaden, MSc. Intuitive Surgical, Sunnyvale, CA, USA

INTRODUCTION

- Despite the growing adoption of robotic-assisted surgery with da Vinci surgical system (dV-RAS), it's efficacy and effectiveness relative to laparoscopic (Lap) or Open approaches for the benign colon remains debated.
- It is essential to consolidate evidence to address existing gaps and provide a comprehensive understanding of the total practice for benign colorectal procedures.

This review and meta-analysis compare perioperative outcomes for dV-RAS, Lap or Open surgery for colectomy or proctectomy in benign colon indications. Benign Colon Indication: Diverticular disease (DD) Indication: Ulcerative colitis (UC) Indication: Crohn's disease (CD)

METHODS

dV-RAS

A PRISMA-guided review and R-based meta-analysis evaluated studies comparing dV-RAS to Lap or Open approaches for benign colon conditions, using PubMed, Embase, and Scopus searches over 14 years (January 1, 2010, to April 15, 2024)


Lap

Open

- Studies were excluded if they were non-English, involved pediatric cases, included mixed procedures or study arms, lacked relevant outcomes, or contained redundant data.
- > Procedures included in the analysis by benian indication:

Indications	Procedures						
DD	 Sigmoidectomy/Sigmoid resection Left colectomy Recto-sigmoid resection Low anterior resection (LAR) Hartmann's procedure 						
UC	 Total proctocolectomy with ileal pouch–anal anastomosis (TPC-IPAA) Proctectomy Proctectomy with IPAA Proctocolectomy Proctocolectomy with IPAA 						
CD	Ileocolic resectionIleocecal resectionColectomy						

RESULTS




Compared to Lap, patients undergoing dV-RAS had:

- ↑ Operative time by **51 minutes**
- ↑ 30-day readmissions by **24%**
- Conversions by 47%
- 30-day postoperative complications by **14%**
- ↓ Length of stay by average **0.5 days**
- > All other outcomes were comparable

Compared to Open, patients undergoing dV-RAS had:

- ↑ Operative time by **87 minutes**
- ↓ Blood transfusions by 47%
- ↓ 30-day postoperative complications by 47%
- ↓ Length of stay by average 2.9 days
- ↓ Anastomotic leak by **61%**
- ↓ Ileus rate by 33%
- > All other outcomes were comparable

Figure 1. Forest plot for Conversion dV-RAS vs Lap



RESULTS

Table 1. Evidence summary: dV-RAS vs Lap

Studies	dV-RAS n	Lap n	Effect size	Heterogeneity	p-value	Conclusion
19	4740	21351	MD: 50.80 [36.75; 64.84]	$p<0.01; I^2=97\%$	p<0.01	Favors LAP
17	5743	16963	OR: 0.53 [0.39; 0.70]	$0.01; I^2=58\%$	p<0.01	Favors dV-RAS
10	4109	15892	OR: 0.88 [0.63; 1.23]	$p=0.04; I^2=50\%$	p=0.46	Comparable
17	4559	18057	MD: -0.54 [-0.79; -0.29]	$p<0.01; I^2=96\%$	p<0.01	Favors dV-RAS
16	4484	19724	OR: 1.00 [0.75; 1.33]	$p < 0.01; I^2 = 67\%$	p=1.00	Comparable
16	3396	20357	OR: 1.04 [0.80; 1.36]		•	Comparable
14	4350	21005	OR: 0.87 [0.65; 1.15]	$p<0.01; I^2=73\%$	p=0.33	Comparable
12	3241	7820	OR: 0.86 [0.77; 0.96]	$p=0.28; I^2=17\%$	p<0.01	Favors dV-RAS
12	3243	16830	OR: 1.24 [1.09; 1.40]	$p=0.59; I^2=0\%$	p<0.01	Favors LAP
15	3422	19996		$p=0.84; I^2=0\%$	p=0.91	Comparable
13	4275	17921	OR: 1.07 [0.59; 1.95]	$p=0.83; I^2=0\%$	p=0.82	Comparable
	19 17 10 17 16 16 14 12 12 15	19 4740 17 5743 10 4109 17 4559 16 4484 16 3396 14 4350 12 3241 12 3243 15 3422	19 4740 21351 17 5743 16963 10 4109 15892 17 4559 18057 16 4484 19724 16 3396 20357 14 4350 21005 12 3241 7820 12 3243 16830 15 3422 19996	19 4740 21351 MD: 50.80 [36.75; 64.84] 17 5743 16963 OR: 0.53 [0.39; 0.70] 10 4109 15892 OR: 0.88 [0.63; 1.23] 17 4559 18057 MD: -0.54 [-0.79; -0.29] 16 4484 19724 OR: 1.00 [0.75; 1.33] 16 3396 20357 OR: 1.04 [0.80; 1.36] 14 4350 21005 OR: 0.87 [0.65; 1.15] 12 3241 7820 OR: 0.86 [0.77; 0.96] 12 3243 16830 OR: 1.24 [1.09; 1.40] 15 3422 19996 OR: 0.99 [0.81; 1.20]	19 4740 21351 MD: 50.80 [36.75; 64.84] p<0.01; l²=97% 17 5743 16963 OR: 0.53 [0.39; 0.70] 0.01; l²=58% 10 4109 15892 OR: 0.88 [0.63; 1.23] p=0.04; l²=50% 17 4559 18057 MD: -0.54 [-0.79; -0.29] p<0.01; l²=96% 16 4484 19724 OR: 1.00 [0.75; 1.33] p<0.01; l²=67% 16 3396 20357 OR: 1.04 [0.80; 1.36] p=0.04; l²=42% 14 4350 21005 OR: 0.87 [0.65; 1.15] p<0.01; l²=73% 12 3241 7820 OR: 0.86 [0.77; 0.96] p=0.28; l²=17% 12 3243 16830 OR: 1.24 [1.09; 1.40] p=0.59; l²=0% 15 3422 19996 OR: 0.99 [0.81; 1.20] p=0.84; l²=0%	19 4740 21351 MD: 50.80 [36.75; 64.84] p<0.01; l²=97% p<0.01 17 5743 16963 OR: 0.53 [0.39; 0.70] 0.01; l²=58% p<0.01 10 4109 15892 OR: 0.88 [0.63; 1.23] p=0.04; l²=50% p=0.46 17 4559 18057 MD: -0.54 [-0.79; -0.29] p<0.01; l²=96% p<0.01 16 4484 19724 OR: 1.00 [0.75; 1.33] p<0.01; l²=67% p=1.00 16 3396 20357 OR: 1.04 [0.80; 1.36] p=0.04; l²=42% p=0.78 14 4350 21005 OR: 0.87 [0.65; 1.15] p<0.01; l²=73% p=0.33 12 3241 7820 OR: 0.86 [0.77; 0.96] p=0.28; l²=17% p<0.01 13 3243 16830 OR: 1.24 [1.09; 1.40] p=0.59; l²=0% p<0.01 15 3422 19996 OR: 0.99 [0.81; 1.20] p=0.84; l²=0% p=0.91

Table 2. Evidence summary: dV-RAS vs Open

Outcomes	Studies	dV-RAS n	Open n	Effect size	Heterogeneity	p-value	Conclusion
Operative time	6	1605	3739	MD: 86.68 [48.93; 124.42]	$p < 0.01; I^2 = 98\%$	p<0.01	Favors Open
Blood transfusions	2	1244	1263	OR: 0.37 [0.24; 0.57]	$p=0.99; I^2=0\%$	p<0.01	Favors dV-RAS
Length of stay	5	1484	1903	MD: -2.85 [-4.84; -0.87]	p<0.01; I ² =84%	p<0.01	Favors dV-RAS
Surgical site infection	5	1529	2179	OR: 0.84 [0.67; 1.05]	$p=0.72; I^2=0\%$	p=0.13	Comparable
Anastomotic leak	4	493	4364	OR: 0.39 [0.19; 0.80]	$p=0.67; I^2=0\%$	p=0.01	Favors dV-RAS
Ileus rate	5	1524	3569	OR: 0.67 [0.54; 0.82]	$p=0.17; I^2=37\%$	p<0.01	Favors dV-RAS
30-day complications	3	1352	1371	OR: 0.53 [0.45; 0.63]	$p = 0.19; I^2 = 40\%$	p<0.01	Favors dV-RAS
30-day readmissions	2	321	660	OR: 1.02 [0.70; 1.49]	$p=0.96; I^2=0\%$	p=0.90	Comparable
30-day reoperations	3	367	2412	OR: 0.83 [0.48; 1.42]	$p=0.69; I^2=0\%$	p=0.49	Comparable
30-day mortality				RD: -0.0002 [-0.0047;	$p=1.00; I^2=0\%$	p=0.95	Comparable
·	4	1478	1817	0.0044]	·	•	·

CONCLUSIONS

- > Our review and analysis suggest that da Vinci surgical system is a feasible and safe option for benign colon surgery.
- Most publications in our meta-analysis focused on DD. Additional research on UC and CD are needed to confirm our findings.

TABLES & REFERENCES



CONTACT

Name: Mansi Mathur

Email: <u>mansi.mathur@intusurg.com</u>